Plazomicin is the newest aminoglycoside and was developed to have improved activity against resistant Enterobacterales. Although streptomycin was the first antituberculosis drug available, it has been supplanted by safer and more effective first-line drugs. If an aminoglycoside is required for treatment of tuberculosis or other mycobacteria, amikacin is now the preferred agent.